ERBB2 and breast cancer: At Fondazione IRCCS Istituto Nazionale dei Tumori—Milano (INT), we developed the 41‐gene classifier TRAR, which is able to identify HER2‐positive BC patients with differential risk of relapse upon treatment with adjuvant H and provides reliable predictive information over established clinical factors in the neoadjuvant setting [11, 12].